Industry news that matters to you.  Learn more

Novo Nordisk and Oxford University Team Up to Develop Novel Treatments for Rheumatoid Arthritis and Other Inflammatory Diseases

Today, Novo Nordisk and the Kennedy Institute of Rheumatology at Oxford University jointly announced a new partnership to develop promising new drug candidates and identify novel biomarkers and treatment targets for rheumatoid arthritis and other autoimmune inflammatory diseases.

Cambridge Healthtech Associates and Nucro-Technics Announce New Market Investigation

Cambridge Healthtech Associates™ (CHA™) and Nucro-Technics, a full-service Pharmaceutical Contract Support Organization, today announced a new partnership focused on a market evaluation of a new biomarker tool set to predict safety adverse events. The goal is develop a novel pre-clinical, fee-for-service assay for use in the evaluation of the potential toxicity of new drug candidates.

Foundation Medicine Announces Collaboration with Array BioPharma

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, recently announced a collaboration with Array BioPharma (NASDAQ: ARRY). Foundation Medicine will use its genomic sequencing and analytic capabilities to assess potentially relevant molecular alterations to assist Array in targeting patients that are most likely to respond to treatment.

The CFIDS Association of America Breaks Ground on Its ‘Institute Without Walls’ to Transform Chronic Fatigue Syndrome Research

The CFIDS Association of America recently announced new additions to its comprehensive research initiative to advance objective diagnosis and effective treatment of chronic fatigue syndrome (CFS): five new grant awards, two new projects using resources from a central biobank and curation of a biomarker “hit list” to guide future research. The new investments total $2 million.

HistoRx Earns Patent on Quantitative Immunoassay Optimization

HistoRx, the leader in quantitative immunohistochemistry (IHC), advances its proprietary position in measurement of biomarkers in tissue through today’s issuance of US Patent 8,121,365 protecting the company’s “Methods and systems for determining optimal dilution of a reagent.” As the first in what HistoRx expects will be a series of broadening patents pertaining to its quantitative methodology, this patent protects the company’s capabilities in optimizing antibody concentration for quantitative immunoassays, methods required to generate high-quality reproducible clinical diagnostic results that precisely relate to biomarker concentrations in tissue sections.